- Home
- IKT
as 11-14-2025 2:27pm EST
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 111.8M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 109.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $4.20 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Inhibikase Therapeutics Inc. News
IKT Breaking Stock News: Dive into IKT Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 hours ago
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
GlobeNewswire
6 months ago
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
MT Newswires
7 months ago
Inhibikase Therapeutics Names David McIntyre as CFO
GlobeNewswire
7 months ago
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Simply Wall St.
7 months ago
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses
GlobeNewswire
8 months ago
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Zacks
8 months ago
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
9 months ago
Inhibikase Announces Expansion of Senior Leadership Team
Compare IKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKT Inhibikase Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.